SGEN Phase 3 AETHERA data due Monday. ALIM PSDV FDA Approval. ACRX NDA update + GLYC delay

Sep 27, 2014 No Comments by

Seattle Genetics, Inc. (Nasdaq:SGEN) will host a conference call and webcast on Monday, September 29, 2014, at 8:30 a.m. Eastern Time (ET) regarding top-line results from its ADCETRIS Phase 3 AETHERA clinical trial for Hodgkin lymphoma patients at risk of relapse following autologous stem cell transplant. Alimera Sciences, Inc. (NASDAQ: ALIM) and pSivida Corp. (NASDAQ: […]

Daily News Read more

CEMP Phase 3 data due 1Q 2015 + updates for AKBA ZFGN

Sep 25, 2014 No Comments by

Akebia Therapeutics, Inc. (NASDAQ:AKBA) announced that the first patient has been dosed in a Phase 2 clinical study of AKB-6548 in patients with anemia related to chronic kidney disease (CKD) who are undergoing dialysis. Data are due in 3Q 2015. Data from their separate Phase 2b trial of AKB-6548 for the treatment of anemia related to CKD […]

Daily News Read more

Additional trials required for EGLT. ACOR acquires Phase 3 Parkinson’s candidate + LCPN MDGN MNOV updates

Sep 24, 2014 No Comments by

Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that it will acquire Civitas Therapeutics, a privately-held biopharmaceutical company, for $525 million in cash. Acorda will obtain worldwide rights to CVT-301, for OFF episodes of Parkinson’s disease (PD).  The Phase 3 trial is expected to commence in early 2015. Egalet Corporation (Nasdaq: EGLT) (Egalet) announced that they will need […]

Daily News Read more

LPCN Phase 3 data due Wednesday. ATOS Breast Aspirator NOT cleared + OPK TTNP ZSPH updates

Sep 23, 2014 No Comments

Lipocine Inc. (Nasdaq:LPCN) announced that they will host a conference call on Wednesday September 24, 2014 at 8:45 a.m. Eastern time to discuss top-line results from its Study of Oral Androgen Replacement (“SOAR”) pivotal Phase 3 clinical trial. A press release will be released prior to the call. Atossa Genetics Inc. (NASDAQ: ATOS) announced that […]

Read more

AVNR offering. THLD trial to continue through to completion + TKMR DVAX AUXL updates

Sep 22, 2014 No Comments

Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) announced that it is offering to sell $200 million of its common stock in an underwritten public offering. Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) has reviewed the merger proposal from Endo International plc and has unanimously determined it is not a superior proposal under the terms of its existing merger agreement with QLT […]

Read more

ADHD Phase 3 data due in about 2 weeks. LTPN offering + updates for HTBX ARGS

Sep 20, 2014 No Comments

Alcobra Ltd. (Nasdaq:ADHD) announced that data from their Phase 3 trial of Metadoxine Extended Release (MDX) in adult Attention Deficit Hyperactivity Disorder (ADHD) patients are due in about two weeks. Argos Therapeutics, Inc. (Nasdaq:ARGS) noted that they are on target to complete enrolment in their pivotal Phase 3 ADAPT trial of AGS-003 for the treatment of metastatic renal cell […]

Read more

FLXN FX006 placed on clinical hold. ONTY offering + updates NVAX VVUS AUXL ISIS OXGN

Sep 18, 2014 No Comments

Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced that the FDA informed the company that a clinical hold has been placed on patient enrollment and dosing in an ongoing Phase 2b clinical trial evaluating FX006 in patients with osteoarthritis (OA) of the knee. The FDA has indicated that the clinical hold is due to a single occurrence of an […]

Read more

ENDO offers to acquire AUXL. NKTR FDA Approval + OGXI AGRX updates

Sep 17, 2014 No Comments

Nektar Therapeutics (NASDAQ:NKTR) announced that their partner AstraZeneca announced that the FDA approved MOVANTIK (naloxegol) tablets as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain. OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced that patient enrollment has been completed in the Phase 3 AFFINITY […]

Read more

AVNR meets endpoint in AVP-923 trial. SLXP Approval. OPXA offering. TGTX finalises SPA agreement + AMRN

Sep 16, 2014 No Comments

Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) announced that it met the primary endpoint in a Phase 2 trial of AVP-923 for the treatment of agitation in patients with Alzheimer’s disease. Treatment with AVP-923 was associated with significantly reduced agitation as measured by the primary endpoint, the agitation/aggression domain score of the neuropsychiatric inventory (NPI) compared to […]

Read more